Skip to content

Ropivacaine plus ketamine versus ropivacaine alone for Cesarean pain

Comparison of ropivacaine plus ketamine with ropivacaine alone in transversus abdominis plane block for pain control after elective Cesarean section

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221125056605N1
Enrollment
54
Registered
2024-03-26
Start date
2024-03-20
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective Cesarean section. Delivery by elective caesarean section

Interventions

Intervention 1: Intervention group: 20 ml ropivacaine 0.2% with lateral approach under ultrasound guide at both sided for transversus abdominis plane block (manufactured by Molteni Co., Italy). Interv

Sponsors

Vice-Chancellery for Research Hormozgan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Pregnancy Candidacy for elective Cesarean American Society of Anesthesiologists (ASA) class I and II Singleton pregnancy

Exclusion criteria

Exclusion criteria: Hypersensitivity to ropivacaine Hypersensitivity to ketamine

Design outcomes

Primary

MeasureTime frame
Pain after Cesarean. Timepoint: At 0, 4, 8, and 12 hours after surgery. Method of measurement: Visual Analogue Scale.

Secondary

MeasureTime frame
Blood pressure. Timepoint: At 0, 4, 8, and 12 hours after surgery. Method of measurement: Standard mercury sphygmomanometer.;Heart rate. Timepoint: Standard mercury sphygmomanometer. Method of measurement: Counting beats per minute.;The interval to pain onset. Timepoint: After surgery. Method of measurement: Clock.;The time of first analgesic requirement. Timepoint: After surgery. Method of measurement: Clock.;The amount of required analgesic. Timepoint: Within 24 hours of surgery. Method of measurement: Mg analgesic used.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElahe Soleimani

Bandare-abbas University of Medical Sciences

drelahesoleimani@gmail.com+98 76 3334 5009

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026